Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21140787 | 1.00 | SRD5A2 (0.69) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL9226234 | 0.89 | SRD5A2 (0.68) | SRD5A2CYP3A4ALDH1A1HSD17B10CYP19A1 | |
| SCHEMBL9226232 | 0.89 | SRD5A2 (0.68) | SRD5A2CYP3A4ALDH1A1HSD17B10CYP19A1 | |
| SCHEMBL17591557 | 0.84 | SRD5A2 (0.63) | SRD5A2CYP19A1 | |
| SCHEMBL17831186 | 0.84 | SRD5A2 (0.63) | SRD5A2CYP19A1 | |
| SCHEMBL15079264 | 0.84 | SRD5A2 (0.63) | SRD5A2CYP19A1 | |
| SCHEMBL6379452 | 0.84 | SRD5A2 (0.63) | SRD5A2CYP19A1 | |
| SCHEMBL11517545 | 0.82 | SRD5A2 (0.73) | SRD5A2CYP3A4CYP19A1MEN1LMNA | |
| SCHEMBL13217277 | 0.82 | SRD5A2 (0.47) | SRD5A2ALDH1A1HSD17B10CYP19A1SHBG | |
| SCHEMBL14199313 | 0.82 | SRD5A2 (0.50) | SRD5A2CYP3A4TDP1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | Sage Therpeutics, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4144746-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3909966-A1 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210139531-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210061849-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210061850-A1 | NEUROACTIVE STERIODS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10822370-B2 | 19-nor neuroactive steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3705488-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200165291-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20170233432-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9512165-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160108080-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2014169833-A9 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2015180679-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2014169836-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014169833-A1 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| EP-2215104-A1 | 11 -FLUORO-3-ACETOXYESTRA-3,5-DIENE-17-ON AND METHOD FOR THE PRODUCTION THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053008-A1 | 11Β-FLUORO-3-ACETOXYESTRA-3,5-DIENE-17-ON AND METHOD FOR THE PRODUCTION THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108080-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | NR3C2, CYP11B1, NR3C1 | SRD5A2 578/4885CYP3A4 197/4885CYP2C9 285/4885 |
| US-20200165291-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CNR1, NR3C2, CNR2 | SRD5A2 484/4885CYP3A4 284/4885CYP2C9 575/4885 |
| US-20210061850-A1 | NEUROACTIVE STERIODS, COMPOSITIONS, AND USES THEREOF | HSD3B1, HTR3B, HSD3B2 | SRD5A2 256/4885CYP3A4 258/4885CYP2C9 535/4885 |
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, HSD3B2 | SRD5A2 230/4885CYP3A4 357/4885CYP2C9 421/4885 |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | NR3C2, NR3C1, CYP11B1 | SRD5A2 454/4885CYP3A4 197/4885CYP2C9 264/4885 |
| US-20210139531-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | SRD5A2 230/4885CYP3A4 357/4885CYP2C9 421/4885 |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | SRD5A2 230/4885CYP3A4 357/4885CYP2C9 421/4885 |
| US-20170233432-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | SRD5A2 230/4885CYP3A4 357/4885CYP2C9 421/4885 |
| US-10822370-B2 | 19-nor neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, HSD3B2 | SRD5A2 230/4885CYP3A4 357/4885CYP2C9 421/4885 |
| US-20210061849-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CNR1, NR3C2, CNR2 | SRD5A2 484/4885CYP3A4 284/4885CYP2C9 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.